Study of HS-10516 combo therapy for advanced kidney cancer
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a new combination therapy for people with advanced clear cell kidney cancer that has progressed after at least one prior treatment. It aims to see if adding HS-10516 to standard care can help shrink tumors or slow the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have advanced clear cell kidney cancer that cannot be removed by surgery or has spread, and it got worse after at least one prior systemic treatment.
- You have at least one measurable tumor that hasn't been treated with radiation or has clearly grown after local treatment.
- You are able to perform daily activities with little to no help (ECOG score 0 or 1).
- You agree to use effective contraception if needed, and women cannot be pregnant or breastfeeding during the study and for 12 months after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental therapy using special immune cells engineered to target a protein called CD70 on kidney cancer cells. It may help patients whose cancer has returned or spread after previous treatment.
This trial tests an investigational medicine called HS-IT101 for people with advanced kidney cancer that hasn't responded to standard treatments. The goal is to see if this new therapy can help shrink or control the cancer.
This trial tests a new drug called HS-10516 in people with VHL syndrome or advanced kidney cancer. The goal is to see if the drug can shrink tumors and what side effects it might have.
This trial tests a combination of three drugs (SHR-8068, adebrelimab, and another anti-tumor drug) for people with advanced kidney cancer (clear cell type). The goal is to see if the combination works better than current treatments.
This trial tests a combination of two drugs (SLC-3010 and axitinib) versus axitinib alone for people with advanced clear cell kidney cancer that has progressed after initial treatment. It aims to see if the combination is safer and more effective.
This trial tests an experimental drug (HC-7366) combined with an approved targeted therapy (belzutifan) for people with advanced kidney cancer. It aims to see if the combination is safe and works better than either drug alone.
Hear when a new Advanced Clear Cell Renal Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.